Trial Profile

A Qualitative Hybrid III Implementation Study to Identify and Evaluate Strategies for Successful Implementation of the Cabotegravir + Rilpivirine Long-acting Injectable Regimen in the US

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 16 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabotegravir (Primary) ; Cabotegravir+rilpivirine (Primary) ; Rilpivirine (Primary)
Indications HIV-1 infections
Focus Registrational; Therapeutic Use
Acronyms CUSTOMIZE
Sponsors ViiV Healthcare

28 Apr 2022 Status changed from active, no longer recruiting to completed.
21 Jul 2021 Results of findings from staff and patients after 12 months of cabotegravir+rilpivirine (CAB+RPV) LA implementation presented at the 11th International AIDS Society Conference on HIV Science
21 Jul 2021 Results assessing COVID-19 impact on cabotegravir+rilpivirine long-acting implementation outcomes, presented at the 11th International AIDS Society Conference on HIV Science.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com